Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
2007
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
2002
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
2003
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Sensitive liquid chromatography–mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma
2002
Conjugation of Camptothecins to Poly‐(l‐Glutamic Acid)
2000
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma
1996
From traditional Chinese medicine to rational cancer therapy
2007 Standout
CLINICAL STUDIES OF CAMPTOTHECIN AND DERIVATIVES
2003
Breast cancer
2016 Standout
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
2004
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents
1997
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Head and neck cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
2004
Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer
2007 Standout
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Antibody therapy of cancer
2012 Standout
Diagnostic and therapeutic management of cancer of an unknown primary
2003
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Treatment of pancreatic cancer
1997
Gefitinib — a novel targeted approach to treating cancer
2004
Antibodies as therapeutic agents: vive la renaissance!
2003
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
2004
Monoclonal antibodies as therapeutic agents for cancer
2004
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
State-of-the-art management of locally advanced head and neck cancer
2005
Analysis of anticancer drugs: A review
2011 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
The tumor microenvironment and its role in promoting tumor growth
2008 Standout
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
2000
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
2002
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium
2005
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
MicroRNA expression profiles classify human cancers
2005 StandoutNatureNobel
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs
1994 StandoutNatureNobel
New drugs in the treatment of colorectal carcinoma
1998
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
FcRn: the neonatal Fc receptor comes of age
2007 Standout
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy
2010
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
Rituximab-Associated Infections
2010
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel
2005
Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.
2009
General principles of tumor immunotherapy : basic and clinical applications of tumor immunology
2007
Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer?
2006
Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy
2005
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma
1996
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
The Tumor Lysis Syndrome
2011 Standout
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
2006
Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
2006
Biodegradable polymers as biomaterials
2007 Standout
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
2005
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Overview of monoclonal antibodies in cancer therapy: present and promise
2005
The Expanding Role of Systemic Therapy in Head and Neck Cancer
2004
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
2008
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
2004
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
2012
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
2006
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Trends in the Aggressiveness of Cancer Care Near the End of Life
2004 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Germ Cell Tumors
1992
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
2001
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Works of James E. Bradof being referenced
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
2000
Phase II study of amonafide in advanced pancreatic adenocarcinoma
1991
Induction Paclitaxel, Carboplatin, and Infusional 5-FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer
2002
Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
1997
Phase II Trial of Merbarone in Pancreatic Carcinoma
1993
Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial
2003
Single-Agent Gefitinib in Patients with Untreated Advanced Non–Small-Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial
2005
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma
2001
Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
2003
Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial
2004
Germ cell malignancies of the ovary. Treatment with vinblastine, actinomycin D, bleomycin and cisplatin containing chemotherapy combinations
1982
Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study
2002
Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial
2001